Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. Article Posted: 1/14/2026. 
Article Highlights - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful can offer considerable short-term upside potential. They also carry substantial downside risk. But even conservative investors should keep an eye on some recently listed stocks, as a few may deserve a place in buy-and-hold portfolios. Wall Street veteran reveals #1 investment trend of 2026 (not AI)
Will you potentially make money or lose money in the U.S. stock market in 2026? According to the 50-year Wall Street legend who invented one of Wall Street's most popular buying and selling indicators – the answer has nothing to do with AI, quantum computing, or cryptos. Instead, it all comes down to the #1 stock he recommends you BUY now… And the #1 stock he recommends you SELL now. One biotechnology company in the healthcare sector that just went public could fit that description. Last Year's IPO Success Stories Last year is a useful reminder that not all IPOs are wildly speculative. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term traders may have benefited from a roughly 359% gain before the stock hit 30 days on the Nasdaq, but longer-term holders are also enjoying strong returns. Some listings demonstrate that IPOs are not limited to high-risk startups. The medical products and services provider Medline (NASDAQ: MDLN), which debuted in December 2025, was founded in 1966 and already commands a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous bacon packages—waited 89 years before going public. Since its January 2025 IPO, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of conditions such as cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing harm to healthy tissue compared with some conventional treatments. Industry consultancy Grand View Research estimates the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it will reach about $35 billion by 2030, a compound annual growth rate of roughly 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the dominant player. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding shifts slowed healthcare listings in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised $318 million in the offering, giving the firm a market cap of about $3.34 billion. According to the company's prospectus, its executive team includes veterans of drug development, approval and commercialization; members of management have played roles in bringing 14 currently FDA-approved products to market. At the product level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision oncology drugs using proprietary technology to attack solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company. That didn't stop it from attracting significant support from Eli Lilly (NYSE: LLY), which anchored the IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares as part of the IPO. This builds on a 2024 collaboration in which Lilly committed $60 million in cash plus an equity investment and potential milestone payments exceeding $1 billion to develop tumor-targeting radiopharmaceuticals with Aktis. The significance of Lilly's backing is notable. At roughly $1.01 trillion, Eli Lilly is among the largest pharmaceutical companies by market cap; its net income jumped nearly 109% year over year from 2023 to 2024. That momentum is likely to be a factor when Lilly reports Q4 and full-year 2025 financial results on Feb. 5. Between its equity stake and the recent $100 million purchase of AKTS shares, Eli Lilly has a sizeable financial interest in Aktis Oncology's future.
| 
